Superficial bladder cancer T1G3: The choice of treatment

BJU International

Volumn 89, Issue 6, 2002, Pages 623-627

  Borkowski, A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; MITOMYCIN C; PROTEIN P53; TUMOR ANTIGEN; TUMOR MARKER; UVOMORULIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTECTOMY; DIAGNOSTIC ACCURACY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; MUSCLE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROTEIN EXPRESSION; RECURRENCE RISK; TRANSURETHRAL RESECTION; TUMOR BIOPSY; URETHRA; UROTHELIUM;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BIOPSY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REOPERATION; URINARY BLADDER NEOPLASMS;

EID: 0036343953     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02696.x     Document Type: Article

References (41)

1. The management of superficial bladder cancer
2. Natural history of early bladder cancer
3. Superficial bladder cancer. Progression and recurrence
4. A combined analysis of European organization for research and treatment of cancer, and medical research council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer
5. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumours: 15-Years outcome
6. Recurrence, progression and success in stage Ta grade 3 bladder tumours treated with low dose BCG
7. The effect on intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a medical research council randomized trial
8. Progression of T1 bladder tumors
9. Radikale zystektomie- oft zu spat?
10. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
11. Radical cystectomy for patients with superficial bladder cancer
12. Radical cystectomy in high-risk nonmuscle-invasive transitional cell carcinoma: Indications and outcomes
13. Uncertainty and outcome of invasive bladder tumors
14. Histopathological 'self control' in transurethral resection of bladder tumours
15. The value of a second transurethral resection in evaluating patients with bladder tumors
16. Significance of bladder biopsies in Ta, T1, bladder tumors; a report from EORTC-GU group
17. Superficial bladder cancer progression and recurrence
18. Microstaging of pT1 transitional cell carcinoma of the bladder: Identification of subgroups with distinct risks of progression
19. The importance of the depth on invasion in stage T1 bladder carcinoma: A prospective cohort study
20. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder
21. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer
22. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS)
23. Tumor markers in the management of bladder cancer
24. Accumulation of nuclear p53 and tumor progression in bladder cancer
25. Editorial comment
26. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer
27. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-years follow-up of prospective randomized trial
28. Management of superficial bladder cancer stage T1 with intravesical bacillus Calmette-Guerin therapy. A 10-years study
29. Long-term results of intravesical therapy for superficial bladder cancer
30. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder
31. Bacillus Calmette-Guerin (BCG) for transitional cell carcinoma
32. BCG does not seem to improve recurrence, progression or survival in T1G3
33. Preventing progression and improving survival with BCG maintenance
34. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra
35. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: Incidence, possible pathogenesis and management
36. Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin
37. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C
38. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and BCG versus mitomycin C alone in patients with superficial bladder cancer
39. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer
40. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study
41. Weekly mitomycin C followed by monthly BCG or alternating monthly interferon-alfa2b and BCG for prophylaxis of recurrent papillary superficial bladder carcinoma